# Allist Pharmaceuticals, Inc. clinical trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Allist Pharmaceuticals, Inc. as lead sponsor, 9 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Allist Pharmaceuticals, Inc.: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/allist-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 8, 2025 | NCT07010419 | A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC... | Allist Pharmaceuticals, Inc. | Phase 3 | Recruiting | NSCLC, Adjuvant Treatment | 338 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07010419) |
| May 14, 2025 | NCT06970639 | A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor... | Allist Pharmaceuticals, Inc. | Phase 3 | Recruiting | NSCLC Patients With Brain Metastasis | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06970639) |
| May 2, 2025 | NCT06956001 | Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation | Allist Pharmaceuticals, Inc. | Phase 3 | Recruiting | EGFR, NSCLC (Advanced Non-small Cell Lung Cancer) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06956001) |
| May 2, 2025 | NCT06955988 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced... | Allist Pharmaceuticals, Inc. | Phase 1 | Recruiting | Locally Advanced or Metastatic Non-small Cell Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06955988) |
| May 16, 2024 | NCT06416410 | JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C... | Allist Pharmaceuticals, Inc. | Phase 3 | Recruiting | Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06416410) |
| December 8, 2023 | NCT06162169 | A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects | Allist Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Subjects | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06162169) |
| August 23, 2023 | NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C... | Allist Pharmaceuticals, Inc. | Phase 2 | Recruiting | KRAS P.G12C, Pancreatic Cancer, Solid Tumor | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06008288) |
| June 27, 2023 | NCT05920941 | Mass Balance Study of \[14C\]JAB-21822 | Allist Pharmaceuticals, Inc. | Phase 1 | Completed | Mass Balance Study in Healthy Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05920941) |
| May 25, 2023 | NCT05875493 | A Food Effect Study of JAB-21822 in Healthy Subjects | Allist Pharmaceuticals, Inc. | Phase 1 | Completed | Food Effect in Healthy Participants | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05875493) |
| July 20, 2022 | NCT05466149 | Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion | Allist Pharmaceuticals, Inc. | Phase 2 | Active not recruiting | NSCLC | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05466149) |
| March 21, 2022 | NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | Allist Pharmaceuticals, Inc. | Phase 1/2 | Recruiting | KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05288205) |
| March 11, 2022 | NCT05276726 | A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 | Allist Pharmaceuticals, Inc. | Phase 1/2 | Recruiting | Non-small Cell Lung Cancer | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05276726) |
| January 18, 2022 | NCT05194995 | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | Allist Pharmaceuticals, Inc. | Phase 1/2 | Active not recruiting | Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05194995) |
| August 17, 2021 | NCT05009329 | A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China | Allist Pharmaceuticals, Inc. | Phase 1/2 | Active not recruiting | NSCLC, Solid Tumor | 315 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05009329) |
| July 12, 2021 | NCT04958967 | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation | Allist Pharmaceuticals, Inc. | Phase 1 | Withdrawn | NSCLC | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04958967) |
| April 26, 2021 | NCT04858958 | Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation | Allist Pharmaceuticals, Inc. | Phase 1 | Completed | NSCLC | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04858958) |
| April 21, 2021 | NCT04853342 | To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive... | Allist Pharmaceuticals, Inc. | Phase 3 | Recruiting | Non-small Cell Lung Carcinoma | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04853342) |
| January 22, 2021 | NCT04720976 | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | Allist Pharmaceuticals, Inc. | Phase 1/2 | Completed | Solid Tumor, NSCLC | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04720976) |
| October 9, 2019 | NCT04121286 | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | Allist Pharmaceuticals, Inc. | Phase 1 | Completed | Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head... | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04121286) |
| May 7, 2019 | NCT03941340 | Study Evaluating the Mass Balance And Biotransformation of Single Dose\[14C\] AST2818 in Chinese Healthy Male Volunteers | Allist Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Male Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03941340) |
| April 24, 2019 | NCT03926182 | Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers | Allist Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Male Volunteers | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03926182) |
| December 27, 2018 | NCT03787992 | Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG） | Allist Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03787992) |
| March 2, 2018 | NCT03452592 | Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M | Allist Pharmaceuticals, Inc. | Phase 2 | Terminated | Advanced NSCLC Patients With T790M | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03452592) |
| April 25, 2017 | NCT03127449 | AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | Allist Pharmaceuticals, Inc. | Not applicable | Terminated | Advanced NSCLC | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03127449) |
| November 25, 2016 | NCT02973763 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer | Allist Pharmaceuticals, Inc. | Phase 1 | Terminated | NSCLC | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02973763) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 5 |
| Phase 2 | 3 |
| Phase 3 | 6 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 9 |
| Completed | 8 |
| Active not recruiting | 4 |
| Terminated | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Colorectal Neoplasms | 2 |
| Carcinoma, Pancreatic Ductal | 2 |
| Appendiceal Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Breast Neoplasms | 1 |
| Noonan Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Sports bars in the United States](https://specstream.ai/data/businesses/sports-bars/united-states)
- [Bar and grill restaurants in the United States](https://specstream.ai/data/businesses/bar-and-grill-restaurants/united-states)
- [Fertilizer stores in the United States](https://specstream.ai/data/businesses/fertilizer-stores/united-states)
- [Natural gas utilities in the United States](https://specstream.ai/data/businesses/natural-gas-utilities/united-states)
- [Telecommunications companies in the United States](https://specstream.ai/data/businesses/telecommunications-companies/united-states)
